Accelerate Your Product to Market with Needle-free Delivery

With PharmaJet’s commercialized products and our technical and clinical expertise, you can progress rapidly from pre-clinical data into successful phase 1, 2 and 3 studies.

35+
Development Partners

 

50+
Active Studies in Progress

 

80+
Studies Completed

Strategic Alliances with PharmaJet

Many leading pharmaceutical, biotechnology, and academic institutions have formed strategic alliances with PharmaJet to use our needle-free injection systems to enhance the delivery of their injected medicines and vaccines.

Needle-free delivery provides a safe and often, more effective alternative to traditional injection techniques. We have needle-free devices for 0.1 ml (intradermal) and 0.5 ml (subcutaneous and intramuscular) dose volumes. Variable dose devices are in late stages of development.

Next generation pharmaceutical development proven process

Click on image to enlarge

Our Needle-free Injection Systems Effectively Deliver

✓ Low and high viscosity medicines

✓ Proteins and peptides

✓ Specialty drug therapies

✓ Nucleic acid-based vaccines and therapeutics

[tropis_info]

PharmaJet Vaccine Partnerships

We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms.

PharmaJet currently has active strategic collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.

Evaxion AI-Immunology
Gennova
Bill & Melinda Gates foundation
nykode therapeutics
Scancell Logo
Seqirus™ A CSL Company
USAMRIID, United States Army Medical Research Institute of Infectious Diseases
Zydus Dedicated to life